BRPI0009746B8 - molécula de veículo contendo plasmídeo pg-pviii compreendendo uma seqúência que codifica uma parte de uma glicoproteína de lissavírus contendo pelo menos o sítio iii da glicoproteína de lissavírus mas não contendo o sítio ii, e, composição imunogênica - Google Patents
molécula de veículo contendo plasmídeo pg-pviii compreendendo uma seqúência que codifica uma parte de uma glicoproteína de lissavírus contendo pelo menos o sítio iii da glicoproteína de lissavírus mas não contendo o sítio ii, e, composição imunogênicaInfo
- Publication number
- BRPI0009746B8 BRPI0009746B8 BRPI0009746A BR0009746A BRPI0009746B8 BR PI0009746 B8 BRPI0009746 B8 BR PI0009746B8 BR PI0009746 A BRPI0009746 A BR PI0009746A BR 0009746 A BR0009746 A BR 0009746A BR PI0009746 B8 BRPI0009746 B8 BR PI0009746B8
- Authority
- BR
- Brazil
- Prior art keywords
- lissavirus
- glycoprotein
- site
- nucleic acids
- pviii
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title abstract 3
- 239000013612 plasmid Substances 0.000 title abstract 2
- 102000003886 Glycoproteins Human genes 0.000 title 2
- 108090000288 Glycoproteins Proteins 0.000 title 2
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011238 DNA vaccination Methods 0.000 abstract 1
- 206010037742 Rabies Diseases 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
"molécula de veículo, composição imunogênica, polipeptídeo, método para tratar um indivíduo, e, plasmídeos pebl1-pv e pviii". a presente invenção provê ácidos nucleicos quiméricos, preferivelmente contidos em um vetor de expressão, que codificam polipeptídeos imunogênicos quiméricos. os ácidos nucleicos codificam pelo menos um sítio iii de uma proteína de lissavírus, que foi constatada como aperfeiçoando a imunogenicidade de epítopos de lissavírus para a proteção contra a raiva. as proteínas e ácidos nucleicos quiméricos podem também conter determinantes antigênicos para outros epítopos que aqueles de lissavírus. deste modo, a invenção provê polipeptídeos e ácidos nucleicos quiméricos, que eliciam uma forte resposta imune para antígenos múltiplos. o uso dos métodos da presente invenção permite a vacinação de dna sem a necessidade de suprir antígenos múltiplos em moléculas de dna separadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12950199P | 1999-04-15 | 1999-04-15 | |
| PCT/IB2000/000564 WO2000063242A1 (en) | 1999-04-15 | 2000-04-17 | Chimeric lyssavirus nucleic acids and polypeptides |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR0009746A BR0009746A (pt) | 2002-01-22 |
| BRPI0009746B1 BRPI0009746B1 (pt) | 2016-08-30 |
| BRPI0009746B8 true BRPI0009746B8 (pt) | 2016-10-04 |
| BRPI0009746C1 BRPI0009746C1 (pt) | 2021-05-25 |
Family
ID=22440282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0009746A BRPI0009746C1 (pt) | 1999-04-15 | 2000-04-17 | molécula de veículo contendo plasmídeo pg-pviii compreendendo uma seqúência que codifica uma parte de uma glicoproteína de lissavírus contendo pelo menos o sítio iii da glicoproteína de lissavírus mas não contendo o sítio ii, e, composição imunogênica |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1171454B1 (pt) |
| AR (2) | AR023505A1 (pt) |
| AT (1) | ATE328003T1 (pt) |
| BR (1) | BRPI0009746C1 (pt) |
| CA (1) | CA2370278C (pt) |
| CY (1) | CY1105176T1 (pt) |
| DE (1) | DE60028365T2 (pt) |
| DK (2) | DK1171454T3 (pt) |
| ES (2) | ES2410593T3 (pt) |
| MX (1) | MXPA01010481A (pt) |
| PT (2) | PT1721982E (pt) |
| WO (1) | WO2000063242A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7901691B2 (en) * | 2004-08-13 | 2011-03-08 | Council Of Scientific And Indistrial Research | Chimeric G protein based rabies vaccine |
| TW200907058A (en) | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| CN109111507B (zh) * | 2017-08-22 | 2021-12-24 | 浙江派迪畅科技发展有限公司 | 病毒重组糖蛋白及其真核细胞高效表达方法与应用 |
| CN111040998B (zh) * | 2019-12-25 | 2023-05-05 | 广东省农业科学院动物卫生研究所 | 一种稳定表达狂犬病毒糖蛋白细胞株的构建及其应用 |
-
2000
- 2000-04-14 AR ARP000101749A patent/AR023505A1/es active IP Right Grant
- 2000-04-17 EP EP00917245A patent/EP1171454B1/en not_active Expired - Lifetime
- 2000-04-17 ES ES06112582T patent/ES2410593T3/es not_active Expired - Lifetime
- 2000-04-17 MX MXPA01010481A patent/MXPA01010481A/es active IP Right Grant
- 2000-04-17 DK DK00917245T patent/DK1171454T3/da active
- 2000-04-17 CA CA2370278A patent/CA2370278C/en not_active Expired - Lifetime
- 2000-04-17 ES ES00917245T patent/ES2267510T3/es not_active Expired - Lifetime
- 2000-04-17 DK DK06112582.9T patent/DK1721982T3/da active
- 2000-04-17 DE DE60028365T patent/DE60028365T2/de not_active Expired - Lifetime
- 2000-04-17 PT PT61125829T patent/PT1721982E/pt unknown
- 2000-04-17 BR BRPI0009746A patent/BRPI0009746C1/pt not_active IP Right Cessation
- 2000-04-17 PT PT00917245T patent/PT1171454E/pt unknown
- 2000-04-17 WO PCT/IB2000/000564 patent/WO2000063242A1/en not_active Ceased
- 2000-04-17 AT AT00917245T patent/ATE328003T1/de active
-
2006
- 2006-08-29 CY CY20061101211T patent/CY1105176T1/el unknown
-
2008
- 2008-04-01 AR ARP080101360A patent/AR065908A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60028365D1 (de) | 2006-07-06 |
| DE60028365T2 (de) | 2007-04-12 |
| WO2000063242A8 (en) | 2001-03-22 |
| MXPA01010481A (es) | 2002-03-27 |
| CY1105176T1 (el) | 2010-03-03 |
| WO2000063242A1 (en) | 2000-10-26 |
| AR023505A1 (es) | 2002-09-04 |
| ATE328003T1 (de) | 2006-06-15 |
| EP1171454B1 (en) | 2006-05-31 |
| DK1171454T3 (da) | 2006-08-21 |
| BRPI0009746C1 (pt) | 2021-05-25 |
| ES2410593T3 (es) | 2013-07-02 |
| BR0009746A (pt) | 2002-01-22 |
| BRPI0009746B1 (pt) | 2016-08-30 |
| ES2267510T3 (es) | 2007-03-16 |
| EP1171454A1 (en) | 2002-01-16 |
| PT1721982E (pt) | 2013-06-06 |
| DK1721982T3 (da) | 2013-04-29 |
| AR065908A2 (es) | 2009-07-08 |
| PT1171454E (pt) | 2006-09-29 |
| CA2370278C (en) | 2011-08-09 |
| CA2370278A1 (en) | 2000-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1117421E (pt) | Novos metodos para vacinacao terapeutica | |
| AR047345A1 (es) | Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes | |
| BR9809445A (pt) | Polipeptìdeo compreendendo uma porção imunogênica de um antìgeno de m. tubercolosis, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processos para indução de imunidade protetora em um paciente, processo de detecção de tuberculose em um paciente,e , kit de diagnóstico. | |
| EP1847549A3 (en) | Papillomavirus polyprotein constructs | |
| ES2059565T3 (es) | Virus mva de la vacuna, recombinante. | |
| JP2001512748A5 (pt) | ||
| ATE359084T1 (de) | Modifizierter hitzeschockprotein/peptidantigen komplex | |
| DE69930630D1 (de) | B2microglobulin fusionsproteine und varianten mit hoher affinität | |
| KR970705408A (ko) | 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins) | |
| WO2002074920A3 (en) | A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same | |
| NO902251D0 (no) | Fremstilling av gonorrheiske p1-proteiner og vaksiner. | |
| MX9801089A (es) | Proteina hibrida que comprende epitopes estimulantes de celula auxiliar t y epitopes de celula b de la proteina de membrana externa mayor chlamydia trachomatis y su uso como vacuna. | |
| BRPI0009746C1 (pt) | molécula de veículo contendo plasmídeo pg-pviii compreendendo uma seqúência que codifica uma parte de uma glicoproteína de lissavírus contendo pelo menos o sítio iii da glicoproteína de lissavírus mas não contendo o sítio ii, e, composição imunogênica | |
| AR009365A1 (es) | Vacunas del virus de la fiebre aftosa (fmdv), peptidos, secuencias de adn y el uso de los peptidos en sistemas de deteccion y el uso de la vacuna fmdc para la preparacion de una composicion para inmunizar cerdos y ganado vacuno | |
| ATE283254T1 (de) | Cytofectin-dimere und verfahren zu ihrer anwendung | |
| SE8105516L (sv) | Syntetisk dna och forfarande for framstellning derav | |
| WO1993014206A3 (en) | Synthetic peptides for a rubella vaccine | |
| BR9709993A (pt) | Vacina preparação de vacina composição processo para produção de uma preparação imugênica e preparação imugênica | |
| DE69021886D1 (de) | Äusseres membranprotein p1 und peptide von haemophilus influenzae typ b. | |
| FR2724385B1 (fr) | Vaccin de la peritonite infectieuse feline. | |
| WO1998052603A3 (en) | An influenza enveloped dna vaccine | |
| IL82720A0 (en) | Recombinant polypeptide containing the amino acid sequence of the protein of feline leukemia virus,expression vehicles,plasmids coding for said protein,method for production thereof and pharmaceutical compositions | |
| EP1502602A3 (en) | Methods for therapeutic vaccination | |
| TR200002611T2 (tr) | Beta-lipotropin ve kullanımları | |
| BR0016740A (pt) | Antìgenos de esporozoìto de cryptosporidium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B25A | Requested transfer of rights approved |
Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/08/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE A RPI 2382 DE 30/08/2016, A FIM DE FAZER CONSTAR AS PAGINAS DA LISTAGEM DE SEQUEENCIA. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 17/04/2020 |